Literature DB >> 6332857

C3d-K, a kallikrein cleavage fragment of iC3b is a potent inhibitor of cellular proliferation.

M L Thoman, J L Meuth, E L Morgan, W O Weigle, T E Hugli.   

Abstract

The C3d-K fragment generated from human iC3b by plasma kallikrein is a potent suppressant of cellular proliferation. Originally characterized as inhibiting human and murine T lymphocyte function, C3d-K is shown in these studies to suppress mitogen-induced B cell growth, the spontaneous proliferation of several tumor cell lines, as well as all forms of T cell proliferation, including that induced by interleukin 2 (IL 2). In addition, synthesis of IL 2 in mixed lymphocyte cultures is blocked by C3d-K, but not IL 2 synthesis induced by Con A. The C3d-K fragment has no effect on resting cells; however, sensitivity to the inhibitory effect of C3d-K is acquired during the activation process. Because the proliferation of mitogen-activated spleen cells is not inhibited by exposure to C3d-K for the initial 24 hr of culture, only late steps in the cell activation process are C3d-K sensitive. When C3d-K is present throughout the course of the 72-hr culture, suppression was observed. Data obtained with the tumor cell lines suggest that once suppression is achieved, it is long-lasting even in the absence of C3d-K.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6332857

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  13 in total

1.  Molecular intercommunication between the complement and coagulation systems.

Authors:  Umme Amara; Michael A Flierl; Daniel Rittirsch; Andreas Klos; Hui Chen; Barbara Acker; Uwe B Brückner; Bo Nilsson; Florian Gebhard; John D Lambris; Markus Huber-Lang
Journal:  J Immunol       Date:  2010-09-24       Impact factor: 5.422

2.  Mapping of the C3d receptor (CR2)-binding site and a neoantigenic site in the C3d domain of the third component of complement.

Authors:  J D Lambris; V S Ganu; S Hirani; H J Müller-Eberhard
Journal:  Proc Natl Acad Sci U S A       Date:  1985-06       Impact factor: 11.205

Review 3.  Interactions between coagulation and complement--their role in inflammation.

Authors:  Katerina Oikonomopoulou; Daniel Ricklin; Peter A Ward; John D Lambris
Journal:  Semin Immunopathol       Date:  2011-08-03       Impact factor: 9.623

Review 4.  Harmful molecular mechanisms in sepsis.

Authors:  Daniel Rittirsch; Michael A Flierl; Peter A Ward
Journal:  Nat Rev Immunol       Date:  2008-10       Impact factor: 53.106

Review 5.  Complement: an overview for the clinician.

Authors:  Juan Carlos Varela; Stephen Tomlinson
Journal:  Hematol Oncol Clin North Am       Date:  2015-04-04       Impact factor: 3.722

Review 6.  Innate immunity activation on biomaterial surfaces: a mechanistic model and coping strategies.

Authors:  Kristina N Ekdahl; John D Lambris; Hans Elwing; Daniel Ricklin; Per H Nilsson; Yuji Teramura; Ian A Nicholls; Bo Nilsson
Journal:  Adv Drug Deliv Rev       Date:  2011-07-08       Impact factor: 15.470

Review 7.  Paroxysmal nocturnal haemoglobinuria.

Authors:  Anita Hill; Amy E DeZern; Taroh Kinoshita; Robert A Brodsky
Journal:  Nat Rev Dis Primers       Date:  2017-05-18       Impact factor: 52.329

8.  T lymphocyte expression of complement receptor 2 (CR2/CD21): a role in adhesive cell-cell interactions and dysregulation in a patient with systemic lupus erythematosus (SLE).

Authors:  E Levy; J Ambrus; L Kahl; H Molina; K Tung; V M Holers
Journal:  Clin Exp Immunol       Date:  1992-11       Impact factor: 4.330

9.  Proteinaceous inhibitors of phospholipase A2 purified from inflammatory sites in rats.

Authors:  Y Suwa; I Kudo; A Imaizumi; M Okada; T Kamimura; Y Suzuki; H W Chang; S Hara; K Inoue
Journal:  Proc Natl Acad Sci U S A       Date:  1990-04       Impact factor: 11.205

Review 10.  Role of complement in multiorgan failure.

Authors:  Daniel Rittirsch; Heinz Redl; Markus Huber-Lang
Journal:  Clin Dev Immunol       Date:  2012-12-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.